{"id":476163,"date":"2020-03-25T13:54:01","date_gmt":"2020-03-25T13:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476163"},"modified":"2020-03-25T13:54:01","modified_gmt":"2020-03-25T13:54:01","slug":"peanut-allergy-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peanut-allergy-pipeline-insight-2020_476163.html","title":{"rendered":"Peanut Allergy Pipeline Insight 2020"},"content":{"rendered":"
\"Peanut<\/a><\/div>\n
“Peanut Allergy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview and Peanut Allergy treatment guidelines.<\/div>\n

DelveInsight launched its new report on Peanut Allergy Pipeline Insight, 2020<\/a><\/p>\n

“Peanut Allergy Pipeline Insight, 2020<\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces in-depth Peanut Allergy commercial assessment and clinical assessment of the Peanut Allergy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Key facts of the report:<\/strong>
1. France had the highest prevalent population of Peanut Allergy with 614,959 cases, followed by Germany and the United Kingdom.
2. The total cases of mild and moderate to severe Peanut Allergy in the US varied as 2,341,384 and 1,153,219 respectively. <\/p>\n

Report insights: <\/strong>
1. All of the companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Peanut Allergy treatment.
3. Peanut Allergy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n

\"\"<\/strong><\/p>\n

Download free report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/peanut-allergy-pipeline-insight<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction
2. Peanut Allergy
2.1. Overview
2.2. History
2.3. Peanut Allergy Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Peanut Allergy Diagnosis
2.6.1. Diagnostic Guidelines
3. Peanut Allergy Current Treatment Patterns
3.1. Peanut Allergy Treatment Guidelines
4. Peanut Allergy – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Peanut Allergy companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Peanut Allergy Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis
4.1.2.3. Peanut Allergy Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono \/ Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Peanut Allergy Late Stage Products (Phase-III)
7. Peanut Allergy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Peanut Allergy Discontinued Products
13. Peanut Allergy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report<\/em>
14. Peanut Allergy Key Companies
15. Peanut Allergy Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Peanut Allergy Unmet Needs
18. Peanut Allergy Future Perspectives
19. Peanut Allergy Analyst Review 
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation <\/p>\n

Related reports:<\/strong><\/p>\n

Peanut Allergy – Epidemiology Forecast to 2030<\/a> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Peanut Allergy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476163","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476163"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}